Pages that link to "Q35894347"
Jump to navigation
Jump to search
The following pages link to Therapeutic cancer vaccines: current status and moving forward (Q35894347):
Displaying 50 items.
- Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm (Q26747699) (← links)
- Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines (Q26772715) (← links)
- Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches (Q26774312) (← links)
- The Concept of Hormesis in Cancer Therapy - Is Less More? (Q26800519) (← links)
- Combination regimens of radiation therapy and therapeutic cancer vaccines: mechanisms and opportunities (Q26851710) (← links)
- Anti-cancer vaccines - a one-hit wonder? (Q26995164) (← links)
- The evolution of poxvirus vaccines (Q26995905) (← links)
- An updated overview of HPV-associated head and neck carcinomas (Q27014019) (← links)
- The development of immunoconjugates for targeted cancer therapy (Q27021990) (← links)
- Surgical Stress Abrogates Pre-Existing Protective T Cell Mediated Anti-Tumor Immunity Leading to Postoperative Cancer Recurrence (Q27345519) (← links)
- The interplay of immunotherapy and chemotherapy: harnessing potential synergies (Q28081893) (← links)
- Endoplasmic reticulum chaperones and their roles in the immunogenicity of cancer vaccines (Q28084299) (← links)
- Design of universal cancer vaccines using natural tumor vessel-specific antigens (SANTAVAC) (Q28087470) (← links)
- Therapeutic cancer vaccines and combination immunotherapies involving vaccination (Q28397609) (← links)
- PBOV1 is a human de novo gene with tumor-specific expression that is associated with a positive clinical outcome of cancer (Q28708968) (← links)
- The immunocytokine NHS-IL12 as a potential cancer therapeutic (Q33688398) (← links)
- Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer (Q33689478) (← links)
- Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment (Q33718182) (← links)
- Chemokines as Cancer Vaccine Adjuvants. (Q33792344) (← links)
- Malignant peritoneal mesothelioma - a rare cause of laparotomy (Q33871712) (← links)
- Next-generation cancer vaccine approaches: integrating lessons learned from current successes with promising biotechnologic advances (Q33973408) (← links)
- Cross-sectional and longitudinal analysis of cancer vaccination trials registered on the US Clinical Trials Database demonstrates paucity of immunological trial endpoints and decline in registration since 2008 (Q34306503) (← links)
- Human cell-based artificial antigen-presenting cells for cancer immunotherapy (Q34391263) (← links)
- Modeling putative therapeutic implications of exosome exchange between tumor and immune cells (Q34407541) (← links)
- Clinical use of dendritic cells for cancer therapy. (Q34421850) (← links)
- EGFR T790M mutation as a possible target for immunotherapy; identification of HLA-A*0201-restricted T cell epitopes derived from the EGFR T790M mutation (Q35040888) (← links)
- InCVAX--a novel strategy for treatment of late-stage, metastatic cancers through photoimmunotherapy induced tumor-specific immunity (Q35108944) (← links)
- Peptide-pulsed dendritic cells have superior ability to induce immune-mediated tissue destruction compared to peptide with adjuvant (Q35125382) (← links)
- A search for novel cancer/testis antigens in lung cancer identifies VCX/Y genes, expanding the repertoire of potential immunotherapeutic targets (Q35429274) (← links)
- Surgical cytoreduction restores the antitumor efficacy of a Listeria monocytogenes vaccine in malignant pleural mesothelioma (Q35768107) (← links)
- Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer (Q35864700) (← links)
- Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination (Q35886450) (← links)
- Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory study (Q35886589) (← links)
- Experimental studies of a vaccine formulation of recombinant human VEGF antigen with aluminum phosphate (Q36256394) (← links)
- Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy (Q36378276) (← links)
- Vaccine-mediated immunotherapy directed against a transcription factor driving the metastatic process. (Q36420021) (← links)
- The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic. (Q36544576) (← links)
- Antigen-coated poly α-hydroxy acid based microparticles for heterologous prime-boost adenovirus based vaccinations (Q36569221) (← links)
- Personalized peptide vaccination: a novel immunotherapeutic approach for advanced cancer (Q36631314) (← links)
- Chitin, chitosan, and glycated chitosan regulate immune responses: the novel adjuvants for cancer vaccine (Q36702887) (← links)
- Vascular normalization as an emerging strategy to enhance cancer immunotherapy (Q36847357) (← links)
- Targeting of antigens to B lymphocytes via CD19 as a means for tumor vaccine development (Q36864003) (← links)
- Promising systemic immunotherapies in head and neck squamous cell carcinoma (Q36883848) (← links)
- The immune system and inflammation in breast cancer (Q37033451) (← links)
- Cross-platform comparison of independent datasets identifies an immune signature associated with improved survival in metastatic melanoma (Q37046631) (← links)
- IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity (Q37052943) (← links)
- Immunotherapeutic strategies to target prognostic and predictive markers of cancer (Q37126006) (← links)
- Peptidases released by necrotic cells control CD8+ T cell cross-priming (Q37259198) (← links)
- Production of recombinant immunotherapeutics for anticancer treatment: the role of bioengineering (Q37269115) (← links)
- Expression of leukotriene B₄ receptor-1 on CD8⁺ T cells is required for their migration into tumors to elicit effective antitumor immunity (Q37274068) (← links)